Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Cancer. 2007 Sep;7(9):701-6.

Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer.

Author information

  • 1Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19,111, USA. Louis.Weiner@fccc.edu

Abstract

The potential of monoclonal antibodies to effectively treat cancer is beginning to be widely acknowledged. Advances in antibody engineering make it possible to produce various recombinant proteins that exploit the specificity of the antibody-combining site to manipulate tumour-related signalling, and to stimulate anti-tumour immune responses. Future advances in the field will rely on the improved identification of functional antibody targets to perturb cancer-relevant signalling, and by the improved selection of tumours that can be effectively treated. These advances will be complemented by the use of antibodies that induce clinically meaningful host-protective immune responses. But, can we afford this progress?

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk